Sunshine Biopharma Inc (SBFM) - Total Liabilities
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has total liabilities worth $7.04 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SBFM net asset momentum to track the company's year-over-year net asset growth rate.
Sunshine Biopharma Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Sunshine Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. See SBFM cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Sunshine Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of Sunshine Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sumber Mas Konstruksi Tbk PT
JK:SMKM
|
Indonesia | Rp5.08 Billion |
|
Ranplan Group
ST:RPLAN
|
Sweden | Skr14.91 Million |
|
Dongil Technology Ltd
KQ:032960
|
Korea | ₩3.59 Billion |
|
Akbar Indomakmur Stimec Tbk
JK:AIMS
|
Indonesia | Rp4.84 Billion |
|
Sonim Technologies Inc
NASDAQ:SONM
|
USA | $50.62 Million |
|
BuilderSmart Public Company Limited
BK:BSM
|
Thailand | ฿737.57 Million |
|
Lupaka Gold Corp.
V:LPK
|
Canada | CA$408.58K |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
India | Rs464.56 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Sunshine Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sunshine Biopharma Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sunshine Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sunshine Biopharma Inc (2007–2025)
The table below shows the annual total liabilities of Sunshine Biopharma Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.04 Million | -0.27% |
| 2024-12-31 | $7.06 Million | +14.99% |
| 2023-12-31 | $6.14 Million | -22.46% |
| 2022-12-31 | $7.92 Million | +297.62% |
| 2021-12-31 | $1.99 Million | -0.45% |
| 2020-12-31 | $2.00 Million | +139.98% |
| 2019-12-31 | $833.53K | -30.67% |
| 2018-12-31 | $1.20 Million | +44.71% |
| 2017-12-31 | $830.85K | +203.11% |
| 2016-12-31 | $274.10K | -78.42% |
| 2015-12-31 | $1.27 Million | +139.23% |
| 2014-12-31 | $531.00K | +1263.29% |
| 2013-12-31 | $38.95K | -39.49% |
| 2012-12-31 | $64.37K | +1774.40% |
| 2011-12-31 | $3.43K | -69.89% |
| 2010-12-31 | $11.40K | -20.33% |
| 2009-12-31 | $14.31K | -37.05% |
| 2008-12-31 | $22.74K | +1415.93% |
| 2007-12-31 | $1.50K | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more